Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Price Target at $34.50

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been given a consensus recommendation of “Hold” by the five ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $34.50.

XFOR has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 8th. Wall Street Zen downgraded shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Stifel Nicolaus set a $10.00 price target on X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 5th. Finally, Zacks Research lowered X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th.

Insider Activity

In other X4 Pharmaceuticals news, Chairman Adam R. Craig acquired 86,206 shares of the company’s stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average price of $2.90 per share, for a total transaction of $249,997.40. Following the acquisition, the chairman directly owned 376,087 shares in the company, valued at $1,090,652.30. This represents a 29.74% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 2.15% of the stock is owned by corporate insiders.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors have recently modified their holdings of XFOR. Kingdon Capital Management L.L.C. increased its stake in shares of X4 Pharmaceuticals by 41.8% in the first quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock valued at $1,655,000 after buying an additional 2,063,000 shares during the period. Nantahala Capital Management LLC bought a new stake in shares of X4 Pharmaceuticals in the 3rd quarter valued at $7,621,000. Pale Fire Capital SE increased its position in shares of X4 Pharmaceuticals by 45.2% during the first quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock worth $481,000 after buying an additional 633,398 shares during the period. Rosalind Advisors Inc. acquired a new position in X4 Pharmaceuticals in the third quarter valued at $5,283,000. Finally, Deep Track Capital LP bought a new stake in X4 Pharmaceuticals during the third quarter valued at $3,839,000. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock opened at $3.91 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $26.83. The stock has a market capitalization of $341.89 million, a P/E ratio of -0.39 and a beta of 0.42. The stock has a fifty day moving average of $3.56 and a 200-day moving average of $3.02.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.10. The firm had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $2.05 million. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%. On average, sell-side analysts expect that X4 Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.